Systematic review – alopecia areata and tofacitinib in paediatric patients

References

• Nina Otberg JS. Alopecia Areata. Fitzpatrick's Dermatology. Volume 1. 9th Edition. Irving (TX): McGraw Hill; 2018.
   Google Scholar
• Rencz F, Gulácsi L, Péntek M, et al. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol 2016;175:561–571.
   PubMed Web of Science ®Google Scholar
• Rork JF, Rashighi M, Harris JE. Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr 2016;28:463–469.
   PubMed Web of Science ®Google Scholar
• Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42:759–773.
   PubMed Web of Science ®Google Scholar
• Lai VWY, Bokhari L, Sinclair R. Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. Int J Dermatol 2021;60:1135–1139.
   PubMedGoogle Scholar
• Aşkın Ö, Yücesoy SN, Coşkun E, et al. Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata. Anais Brasileiros de Dermatologia 2021;96:551–557.
   PubMedGoogle Scholar
• Pfizer. Xeljanz: EPAR – Product Information – Summary of Product Characteristics. European Medicines Agency. 2021.
   Google Scholar
• Pfizer. P/0134/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz), (EMEA-000576-PIP01-09-M10). European Medicines Agency. 2019.
   Google Scholar
• Sonthalia S, Aggarwal P. Oral tofacitinib: contemporary appraisal of its role in dermatology. Indian Dermatol Online J 2019;10:503–518.
   PubMedGoogle Scholar
• Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 2016;1:e89776.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Cohen S, Keystone E, et al. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a phase 3 rheumatoid arthritis population. Semin Arthritis Rheum 2018;48:406–415.
   PubMedGoogle Scholar
• Ruperto N, Brunner HI, Zuber Z, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol 2017;15:86.
   PubMedGoogle Scholar
• Huang Z, Lee PY, Yao X, et al. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics 2019;143:e20182845.
   PubMedGoogle Scholar
• Gregory MH, Ciorba MA, Deepak P, et al. Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab. Inflamm Bowel Dis 2019;25:e87–e88.
   PubMed Web of Science ®Google Scholar
• Dolinger MT, Rolfes P, Phan BL, et al. Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:966–967.
   PubMed Web of Science ®Google Scholar
• Sato S, Matsumoto H, Temmoku J, et al. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib. Rheumatology 2020;59:1773–1775.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Akikusa J, Al-Abadi E, et al. editors. Tofacitinib for the treatment of patients with juvenile idiopathic arthritis: an interim analysis of data up to 5.5 years from an open-label, long-term extension study. Wiley 111 River St, Hoboken 07030-5774, NJ, USA: Arthritis & Rheumatology; 2020.
   Google Scholar
• Ruperto N, Synoverska O, Ting T, et al. OP0291 tofacitinib for the treatment of polyarticular course juvenile idiopathic arthritis: results of a phase 3, randomised, double-blind, placebo-controlled withdrawal study. Annals of the Rheumatic Diseases; 2020.
   Google Scholar
• Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019;33:850–856.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol 2017;76:29–32.
   PubMed Web of Science ®Google Scholar
• Bayart CB, DeNiro KL, Brichta L, et al. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol 2017;77:167–170.
   PubMed Web of Science ®Google Scholar
• Brown L, Skopit S. An excellent response to tofacitinib in a pediatric alopecia patient: a case report and review. J Drugs Dermatol 2018;17:914–917.
   PubMed Web of Science ®Google Scholar
• Putterman E, Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J Am Acad Dermatol 2018;78:1207–1209.e1.
   PubMed Web of Science ®Google Scholar
• Chiang A, Ortenzio F, Juhasz MLW, et al. Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: a case report and review of the literature. JAAD Case Rep 2018;4:733–736.
   PubMedGoogle Scholar
• Patel NU, Oussedik E, Grammenos A, et al. A case report highlighting the effective treatment of alopecia universalis with tofacitinib in an adolescent and adult patient. J Cutan Med Surg 2018;22:439–442.
   PubMed Web of Science ®Google Scholar
• Castelo-Soccio L. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. J Am Acad Dermatol 2017;76:754–755.
   PubMed Web of Science ®Google Scholar
• Akdogan N, Ersoy-Evans S, Doğan S, et al. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata. Dermatol Ther 2019;32:e13118.
   PubMedGoogle Scholar
• Morales-Miranda AY, Bueno-Arias GM, Aguirre-Félix ÓG, et al. Tofacitinib as a treatment of alopecia areata in adolescents. Bol Med Hosp Infant Mex 2019;76:182–187.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. J Am Acad Dermatol 2019;80:568–570.
   PubMed Web of Science ®Google Scholar
• Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata. J Am Acad Dermatol 2019;80:1164–1166.
   PubMed Web of Science ®Google Scholar
• Jerjen R, Meah N, Trindade de Carvalho L, et al. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: a retrospective study. Pediatr Dermatol 2021;38:103–108.
   PubMed Web of Science ®Google Scholar
• Dincer Rota D, Emeksiz MAC, Erdogan FG, et al. Experience with oral tofacitinib in severe alopecia areata with different clinical responses. J Cosmet Dermatol 2021;20:3026–3033.
   PubMedGoogle Scholar
• Berbert Ferreira R, Ferreira SB, Scheinberg MA. An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: a case report and a review of the literature. Clin Case Rep. 2019;7:2539–2542.
   PubMedGoogle Scholar
• Liu LY, King BA. Tofacitinib for the treatment of severe alopecia areata in adults and adolescents. J Investig Dermatol Symp Proc 2018;19:S18–s20.
   PubMedGoogle Scholar
• Guo L, Feng S, Sun B, et al. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol 2020;34:192–201.
   PubMed Web of Science ®Google Scholar
• de Oliveira AB, Alpalhão M, Filipe P, et al. The role of Janus kinase inhibitors in the treatment of alopecia areata: a systematic review. Dermatol Ther 2019;32:e13053.
   PubMedGoogle Scholar
• Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg 2009;28:15–18.
   PubMed Web of Science ®Google Scholar
• Zafrir Y, Baum S, Greenberger S, et al. [ALOPECIA AREATA]. Harefuah 2016;155:622–625.
   PubMedGoogle Scholar
• Aşkın Ö, Özkoca D, Uzunçakmak TK, et al. Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic. Dermatol Ther 2021;34:e14746.
   PubMedGoogle Scholar